肾内科

订阅

MedSci主页 / 所有栏目 / 肾内科

2019年AUA：临床前数据突显EPI-7386治疗前列腺癌的潜力

2019-05-07 不详 网络

EPI-7386前列腺癌恩杂鲁胺
关注

ESSA是一家专注于开发前列腺癌治疗新疗法的制药公司，近日宣布，将在2019年美国泌尿学会（AUA）年会上公布新一代N末端域雄激素受体抑制剂EPI-7386在去势抵抗前列腺癌模型中的有效性数据。

ESSA是一家专注于开发前列腺癌治疗新疗法的制药公司，近日宣布，将在2019年美国泌尿学会（AUA）年会上公布新一代N末端域雄激素受体抑制剂EPI-7386在去势抵抗前列腺癌模型中的有效性数据。结果显示，在三种临床前动物模型中，EPI-7386表现出良好的代谢特征。在恩杂鲁胺敏感的LNCaP前列腺癌异种移植模型中，EPI-7386具有与恩杂鲁胺类似的抗肿瘤活性。在恩杂鲁胺抗性VCaP前列腺癌异种移植模型中，EPI-7386作为单一药剂或与恩杂鲁胺组合使用均能够提供优异的抗肿瘤活性。

前列腺癌是出自前列腺的恶性肿瘤。癌细胞可转移到骨和淋巴结等部位。前列腺癌早期可能没有症状，晚期可导致排尿困难、尿血、背痛、骨盆疼痛等症状。


原始出处：

http://www.firstwordpharma.com/node/1638726#axzz5nC823Px1

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797299, encodeId=b0cb1e972997f, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue Jan 28 12:37:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003460, encodeId=bf182003460c7, content=<a href='/topic/show?id=901268e007' target=_blank style='color:#2F92EE;'>#EPI-7386#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6870, encryptionId=901268e007, topicName=EPI-7386)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Oct 21 16:37:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693940, encodeId=fdd8169394070, content=<a href='/topic/show?id=dd652993af' target=_blank style='color:#2F92EE;'>#AUA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2993, encryptionId=dd652993af, topicName=AUA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd8129488576, createdName=makuansheng, createdTime=Fri Sep 27 14:37:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040446, encodeId=64bc104044619, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 12:37:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
    2020-01-28 cqlidoudou

    #临床前数据#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1797299, encodeId=b0cb1e972997f, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue Jan 28 12:37:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003460, encodeId=bf182003460c7, content=<a href='/topic/show?id=901268e007' target=_blank style='color:#2F92EE;'>#EPI-7386#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6870, encryptionId=901268e007, topicName=EPI-7386)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Oct 21 16:37:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693940, encodeId=fdd8169394070, content=<a href='/topic/show?id=dd652993af' target=_blank style='color:#2F92EE;'>#AUA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2993, encryptionId=dd652993af, topicName=AUA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd8129488576, createdName=makuansheng, createdTime=Fri Sep 27 14:37:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040446, encodeId=64bc104044619, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 12:37:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
    2019-10-21 fengxx

    #EPI-7386#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1797299, encodeId=b0cb1e972997f, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue Jan 28 12:37:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003460, encodeId=bf182003460c7, content=<a href='/topic/show?id=901268e007' target=_blank style='color:#2F92EE;'>#EPI-7386#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6870, encryptionId=901268e007, topicName=EPI-7386)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Oct 21 16:37:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693940, encodeId=fdd8169394070, content=<a href='/topic/show?id=dd652993af' target=_blank style='color:#2F92EE;'>#AUA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2993, encryptionId=dd652993af, topicName=AUA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd8129488576, createdName=makuansheng, createdTime=Fri Sep 27 14:37:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040446, encodeId=64bc104044619, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 12:37:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
    2019-09-27 makuansheng

    #AUA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1797299, encodeId=b0cb1e972997f, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue Jan 28 12:37:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003460, encodeId=bf182003460c7, content=<a href='/topic/show?id=901268e007' target=_blank style='color:#2F92EE;'>#EPI-7386#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6870, encryptionId=901268e007, topicName=EPI-7386)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Oct 21 16:37:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693940, encodeId=fdd8169394070, content=<a href='/topic/show?id=dd652993af' target=_blank style='color:#2F92EE;'>#AUA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2993, encryptionId=dd652993af, topicName=AUA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd8129488576, createdName=makuansheng, createdTime=Fri Sep 27 14:37:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040446, encodeId=64bc104044619, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 12:37:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
    2019-05-07 misszhang

    前列腺癌相关研究，学习了，谢谢梅斯

    0